HOME >> BIOLOGY >> NEWS
OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine

Watertown, Massachusetts, July 2, 2003 OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that The Johns Hopkins University School of Medicine will begin a Phase I/II clinical trial of the Company's lead vascular targeting agent, Combretastatin A4 Prodrug (CA4P). The study will be conducted in patients with a retinal degenerative disease known as wet age-related macular degeneration (AMD). Between 2 million and 3 million people in the United States have significant vision loss caused by wet AMD.

"From a scientific perspective, this trial is significant because it marks the first study of a vascular targeting agent, initially developed to treat cancer, in patients with wet AMD," said Fred Driscoll, OXiGENE's president and chief executive officer. "From a corporate perspective, this trial strategically broadens our clinical development program into a second major area. Both oncology and ophthalmology offer significant market opportunities with unmet therapeutic needs."

Under the trial protocol, which was reviewed by the U.S. Food and Drug Administration, approximately 20 patients are scheduled to participate in the study. The study is now open for enrollment at Johns Hopkins' Wilmer Eye Institute in Baltimore, Maryland. The trial will be led by Quan Dong Nguyen, M.D., assistant professor of ophthalmology, and Peter Campochiaro, M.D., professor of ophthalmology, at Wilmer. As OXiGENE announced in October 2002, the trial is being funded by The Foundation Fighting Blindness, Inc. (FFB), the nation's premier non-profit eye research organization, whose mission is to discover the causes, treatments and cures for degenerative retinal eye diseases.

"CA4P has exhibited very promising pre-clinical results in preventing and causing regression of choroidal neovascularization, the major cause of severe vision loss in patients with age-related macular degeneration," said Dr. Jerry Chader, the FFB's chief scientific officer and a former sci
'"/>

Contact: Scott Solomon
ssolomon@investorrelations.com
617-542-5300
Sharon Merrill Associates, Inc.
2-Jul-2003


Page: 1 2 3

Related biology news :

1. OXiGENE launches significant expansion of its R&D program in ophthalmology
2. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
3. OXiGENE announces phase II clinical trial of lead anti-tumor compound in thyroid cancer
4. OXiGENE, foundation fighting blindness sign research agreement for phase I/II clinical trial
5. Secretary of Energy announces seven E.O. Lawrence Award Winners
6. Popular Science announces Third Annual Brilliant 10
7. The American Phytopathological Society announces 2004 awards
8. NSF announces six FIBR awards to tackle some of biologys most challenging questions
9. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
10. JGI announces community sequencing program portfolio
11. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2019)... ... 2019 , ... In recent years the neurocognitive effects of ... many cases the magnitude of these deficits and the long-term impact on cognitive ... effects may impact developmental trajectories, and patients are often so unwell at the ...
(Date:4/25/2019)... ... 2019 , ... In a letter sent to U.S. Department ... 62 individual scientists, bioethicists, and biotechnology executives, including past-presidents and current board of ... industry and academia called for collaboration on a binding global moratorium on human ...
(Date:4/25/2019)... ... April 25, 2019 , ... Aniara Diagnostica, a multi-national distributor ... commitment to meeting today’s highest standards for product quality and cost-efficient delivery. ... targeted proteases is needed. Current uses concern protein isolation, removal of reactive proteases ...
Breaking Biology News(10 mins):
(Date:5/14/2019)... (PRWEB) , ... May 14, 2019 , ... Gateway ... expansion, effectively doubling its space from 2,500 to 5,000 square feet. , “This ... Gender DNA tests ,” says Gateway Genomics CEO, Chris Jacob. “The SneakPeek At-Home test, ...
(Date:5/7/2019)... British Columbia (PRWEB) , ... May 06, 2019 ... ... be a go-to resource for the growing number of repositories being asked to ... We are grateful to the team of contributors who are world leaders, who ...
(Date:5/4/2019)... ... 03, 2019 , ... Diopsys Inc, the world leader in ... vision test, a new full field electroretinography (ffERG) protocol designed to detect ... Americans will have glaucoma, with black Americans having the highest prevalence rate. This ...
(Date:5/2/2019)... ... April 30, 2019 , ... The centuries old practice of brewing beer thrives ... craft breweries, and even home brewing clubs scattered across the nation. , But ... when mastered can produce a superb product. Students at South Dakota School of ...
Breaking Biology Technology:
Cached News: